Rare Cancers: Challenges and Roadmap for R&D Innovations

Drug development for Rare cancers is challenging because it is difficult to obtain relevant data from very few patients. The oncology community is increasingly facing a disproportionate fraction of the total burden of cancers, hence, requiring multi-stakeholder cooperation and collaboration to complete rare cancer trials.

Nevertheless, new insights into the biology of rare cancers have led to an explosion in knowledge and the development of targeted agents. In addition, drug development strategies and the availability of new agents for rare cancers are at risk of stalling owing to the ever-increasing complexity and costs of clinical trials. Finding solutions to these problems is imperative to the future of cancer care.

Join our webinar to learn about:

1. Differentiating the Rare cancers from common cancers & complexities at molecular alterations
2. New paradigms in clinical drug development and Innovation pipeline overview – current landscape, new therapeutic targets, and potential combinations
3. Insights on novel solutions and multi-stakeholder efforts to address clinical development challenges for Rare cancers

For more details on FutureBridge’s expertise in Life Sciences visit us at https://www.futurebridge.com/life-sciences/